Abstract
Background There is a growing body of literature implicating angiotensin II in the modulation of tumor associated inflammation and pain. However, the impact of angiotensin converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) on this pathway has not yet been studied in oral cancers. Our objective is to investigate the role of ACEi and ARB pharmacotherapy on preoperative pain and inflammatory biomarkers, neutrophil to lymphocyte ratio (NLR) and monocyte to lymphocyte ratio (MLR), in patients with oral cancer.
Methods We performed a retrospective study on patients who underwent oral cancer surgery. Wilcoxon rank sum test or Kruskal-Wallis analysis were used to evaluate differences in demographic, tumor-related, and preoperative characteristics and among patients using ARBs, ACEis, and no treatment. Multivariable analysis was fitted to estimate the effects of important covariates on severe preoperative pain.
Results 162 patients with oral malignancies were included in the study. After adjusting for significant covariates, patients with perineural invasion were found to have higher levels of pain (p = 0.0278). Likewise, patients taking ARBs were found to have lower levels of perineural invasion (p = 0.035). Our analysis did not demonstrate a significant difference in pain levels when comparing ARBs or ACEis to the no treatment group (p= 0.250). Furthermore, ARB or ACEi use did not significantly alter preoperative NLR (p = 0.701) or MLR (p = 0.869).
Conclusions When compared to no treatment, ARBs and ACEis are not associated with significant analgesic effect or decreased inflammatory scores (NLR, MLR).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is securely stored and available to authors and co-authors of this work. This work is only in pre-preprint status.
